ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.47 USD
0.00 (0.21%)
Updated Apr 24, 2024 04:00 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for ASLAN Pharmaceuticals Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 21 | 57 | 90 | 14 | 22 |
Receivables | 0 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 4 | 4 | 1 | 0 |
Total Current Assets | 24 | 61 | 94 | 16 | 22 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 25 | 61 | 95 | 16 | 23 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 13 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 2 | 8 | 0 | 4 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 2 | 3 | 5 | 3 |
Total Current Liabilities | 13 | 23 | 6 | 11 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 25 | 30 | 31 | 15 | 18 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 53 | 37 | 26 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 64 | 63 | 63 | 62 | 61 |
Capital Surplus | 244 | 224 | 221 | 124 | 117 |
Retained Earnings | -321 | -278 | -227 | -196 | -179 |
Other Equity | 0 | 0 | 0 | 0 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -13 | 8 | 57 | -10 | -1 |
Total Liabilities & Shareholder's Equity | 25 | 61 | 95 | 16 | 23 |
Total Common Equity | -13 | 8 | 57 | -10 | -1 |
Shares Outstanding | 16.30 | 13.90 | 13.90 | 6.40 | 6.40 |
Book Value Per Share | -0.82 | 0.60 | 4.12 | -1.59 | -0.09 |
Fiscal Year End for ASLAN Pharmaceuticals Ltd falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 21 | 41 | 41 | 58 |
Receivables | NA | 0 | 0 | 12 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 3 | 2 | 3 |
Total Current Assets | NA | 24 | 44 | 55 | 60 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 25 | 45 | 55 | 60 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 8 | 4 | 6 | 10 |
Current Portion Long-Term Debt | NA | 2 | 13 | 13 | 11 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 3 | 5 | 2 |
Total Current Liabilities | NA | 13 | 21 | 24 | 23 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 25 | 25 | 24 | 27 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 38 | 46 | 49 | 50 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 64 | 64 | 64 | 64 |
Capital Surplus | NA | 244 | 245 | 242 | 244 |
Retained Earnings | NA | -321 | -309 | -299 | -298 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -13 | -1 | 6 | 10 |
Total Liabilities & Shareholder's Equity | NA | 25 | 45 | 55 | 60 |
Total Common Equity | 0 | -13 | -1 | 6 | 10 |
Shares Outstanding | 16.30 | 16.30 | 16.30 | 16.30 | 13.90 |
Book Value Per Share | 0.00 | -0.82 | -0.05 | 0.39 | 0.71 |